IFN-α/βRβ CRISPR/Cas9 KO Plasmid (m): sc-421048

Overview

Ifnar2 encodes the mouse interferon-α/β receptor subunit IFN-α/βRβ (IFNAR2), a core component of the type I interferon receptor complex that couples extracellular IFN-α/β binding to intracellular JAK–STAT signaling. Upon receptor engagement, IFNAR2 cooperates with IFNAR1 to activate TYK2 and JAK1, driving phosphorylation of STAT1/STAT2 and formation of ISGF3 to induce interferon-stimulated genes that regulate antiviral defense, antigen presentation, and innate immune cell programming. This pathway shapes inflammatory set points and crosstalk with NF-κB and MAPK signaling, influencing cytokine networks and immune homeostasis. Dysregulated IFNAR2-dependent signaling has been implicated in immune-mediated pathology and altered susceptibility to infection and inflammation, making it a relevant target for mechanistic studies in immunology and host–pathogen biology.

IFN-α/βRβ CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ifnar2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ifnar2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ifnar2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IFN-α/βRβ protein expression.

This CRISPR knockout system enables efficient generation of Ifnar2-deficient cell models for investigation of IFN-α/βRβ signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Ifnar2 exon(s) critical for IFN-α/βRβ function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Ifnar2 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by IFN-α/βRβ CRISPR/Cas9 KO Plasmid (m) and IFN-α/βRβ CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ifnar2 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by IFN-α/βRβ HDR Plasmid (m) and IFN-α/βRβ HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ifnar2 homology arms to support homology-directed repair at defined Ifnar2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.